💊 A high quality GLP1 pill: once-daily Orforglipron
The ATTAIN-1 trial produced impressive results at 72 weeks
The name is hard to pronounce, but Orforglipron is a promising GLP1 Receptor Agonist under development by Eli Lilly which we first covered way back in September 2024, and most recently this summer:
Preliminary results from the latest trial of Orforglipron (ATTAIN-1) have landed:
We dive into the results of the study along with a comparison of Orforglipron to other GLP1s: